News | Peripheral Artery Disease (PAD) | May 15, 2018

SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection

The document is first of its kind to provide device-focused recommendations based on a review of comparative effectiveness data

SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection

May 15, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the selection of specific categories of devices when endovascular therapy (EVT) is indicated. The purpose of this document, which is the first of its kind, is to provide a review of comparative effectiveness data, including safety and efficacy of femoral-popliteal (FP) devices. The document also provides clinicians with guidance and recommendations for device selection when these devices are intended as the definitive or adjunctive therapy.

The document is available in early-view online in SCAI’s official journal, Catheterization and Cardiovascular Interventions.[1]

There is widespread uncertainty about device selection for EVT due to clinicians having many options and opinions, with limited data to distinguish between them. The SCAI writing group reviewed and considered data on safety, efficacy and cost-effectiveness when making device-specific recommendations. Data sources included randomized clinical trials, meta-analyses, nonrandomized trials, observational studies, case series and registry data.

“SCAI has a long history of prioritizing quality initiatives in the field of endovascular therapy for peripheral artery disease. Device choices for endovascular therapy, particularly in the femoral-popliteal interventions, remain challenging due to a wide spectrum of available device options and a paucity of comparative effectiveness data,” said Dmitriy Feldman, M.D., FSCAI, chair of the writing group. “Current guidelines do not address the selection of specific devices when endovascular therapy is indicated. This is the first SCAI-led device-focused consensus guidelines document, which provides a focused review of comparative effectiveness and safety data for femoral-popliteal devices,” Feldman continued.

The document, which makes recommendations for both definitive and adjunctive therapy scenarios, identified several areas for future research, including trials on value and cost-effectiveness of devices in specific clinical circumstances and lesion subsets. In addition, the guidelines recommend that future studies adopt the Peripheral Academic Research Consortium (PARC) definitions for clinically meaningful outcomes and endpoints.

The recommendations in this consensus guidelines document are a first step to provide clinicians with relevant anatomical scenarios to guide device selection based on strength and quality of evidence for comparative effectiveness, durability and expert opinion.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

For more information: www.scai.org

 

Reference:

1. Dmitriy N. Feldman, Ehrin J. Armstrong, Herbert D. Aronow, et al. SCAI consensus guidelines for device selection in femoral‐popliteal arterial interventions. Catheterization and Cardiovascular Interventions. Catheterization and Cardiovascular Interventions. First published: 24 April 2018 https://doi.org/10.1002/ccd.27635
 


Related Content

News | Peripheral Artery Disease (PAD)

June 6, 2025 – A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 ...

Home June 06, 2025
Home
News | Peripheral Artery Disease (PAD)

Feb. 3, 2025 — Today, Peripheral Artery Disease (PAD) affects 10 million Americans and is the most common cause of limb ...

Home February 04, 2025
Home
News | Peripheral Artery Disease (PAD)

Jan. 13, 2025 – R3 Vascular Inc., a medical device company dedicated to treating peripheral arterial disease (PAD) ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

A new study reports persistent disparities in outcomes for people with peripheral artery disease (PAD) and its more ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

Dec. 13, 2024 – Sensome has announced positive results from two studies of its Clotild Smart Guidewire System ...

Home December 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...

Home December 03, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial ...

Home November 08, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
Subscribe Now